nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—CRABP1—esophageal cancer	0.668	0.917	CbGaD
Alitretinoin—ABCB1—esophageal cancer	0.0604	0.0828	CbGaD
Alitretinoin—CRABP1—neck—esophageal cancer	0.00383	0.112	CbGeAlD
Alitretinoin—RXRG—neck—esophageal cancer	0.00303	0.0888	CbGeAlD
Alitretinoin—CRABP1—bronchus—esophageal cancer	0.00257	0.0752	CbGeAlD
Alitretinoin—Acitretin—CYP26A1—esophageal cancer	0.00251	0.399	CrCbGaD
Alitretinoin—CRABP2—bronchus—esophageal cancer	0.00232	0.068	CbGeAlD
Alitretinoin—CRABP1—trachea—esophageal cancer	0.0023	0.0676	CbGeAlD
Alitretinoin—CRABP2—smooth muscle tissue—esophageal cancer	0.00227	0.0666	CbGeAlD
Alitretinoin—CRABP2—trachea—esophageal cancer	0.00208	0.0611	CbGeAlD
Alitretinoin—RARB—bronchus—esophageal cancer	0.00208	0.0609	CbGeAlD
Alitretinoin—CRABP2—digestive system—esophageal cancer	0.00179	0.0526	CbGeAlD
Alitretinoin—Vitamin A—CYP26A1—esophageal cancer	0.00175	0.279	CrCbGaD
Alitretinoin—Tretinoin—CRABP1—esophageal cancer	0.00162	0.259	CrCbGaD
Alitretinoin—CRABP2—lung—esophageal cancer	0.0015	0.0439	CbGeAlD
Alitretinoin—RARB—lung—esophageal cancer	0.00134	0.0393	CbGeAlD
Alitretinoin—RARG—digestive system—esophageal cancer	0.00131	0.0383	CbGeAlD
Alitretinoin—RXRB—lung—esophageal cancer	0.00123	0.0361	CbGeAlD
Alitretinoin—RARG—lung—esophageal cancer	0.00109	0.032	CbGeAlD
Alitretinoin—RARA—lung—esophageal cancer	0.00103	0.0301	CbGeAlD
Alitretinoin—RARB—lymph node—esophageal cancer	0.000916	0.0269	CbGeAlD
Alitretinoin—RARG—lymph node—esophageal cancer	0.000747	0.0219	CbGeAlD
Alitretinoin—RARA—lymph node—esophageal cancer	0.000703	0.0206	CbGeAlD
Alitretinoin—CYP1A2—digestive system—esophageal cancer	0.000456	0.0134	CbGeAlD
Alitretinoin—Tretinoin—CYP2A6—esophageal cancer	0.000394	0.0628	CrCbGaD
Alitretinoin—CYP1A2—lung—esophageal cancer	0.000381	0.0112	CbGeAlD
Alitretinoin—ABCB1—epithelium—esophageal cancer	0.000307	0.009	CbGeAlD
Alitretinoin—ABCB1—trachea—esophageal cancer	0.000272	0.00796	CbGeAlD
Alitretinoin—ABCB1—digestive system—esophageal cancer	0.000234	0.00685	CbGeAlD
Alitretinoin—ABCB1—lung—esophageal cancer	0.000195	0.00572	CbGeAlD
Alitretinoin—Mouth ulceration—Methotrexate—esophageal cancer	0.00019	0.00163	CcSEcCtD
Alitretinoin—Bladder pain—Methotrexate—esophageal cancer	0.00019	0.00163	CcSEcCtD
Alitretinoin—Urinary tract disorder—Cisplatin—esophageal cancer	0.00019	0.00163	CcSEcCtD
Alitretinoin—Urethral disorder—Cisplatin—esophageal cancer	0.000189	0.00162	CcSEcCtD
Alitretinoin—Dry skin—Capecitabine—esophageal cancer	0.000188	0.00162	CcSEcCtD
Alitretinoin—Pulmonary oedema—Methotrexate—esophageal cancer	0.000187	0.00161	CcSEcCtD
Alitretinoin—Visual impairment—Cisplatin—esophageal cancer	0.000185	0.00159	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000185	0.00159	CcSEcCtD
Alitretinoin—Nasopharyngitis—Capecitabine—esophageal cancer	0.000183	0.00158	CcSEcCtD
Alitretinoin—Sepsis—Methotrexate—esophageal cancer	0.000182	0.00157	CcSEcCtD
Alitretinoin—Gastritis—Capecitabine—esophageal cancer	0.000181	0.00156	CcSEcCtD
Alitretinoin—Eye disorder—Cisplatin—esophageal cancer	0.00018	0.00155	CcSEcCtD
Alitretinoin—Tinnitus—Cisplatin—esophageal cancer	0.000179	0.00154	CcSEcCtD
Alitretinoin—Lymphadenopathy—Methotrexate—esophageal cancer	0.000179	0.00154	CcSEcCtD
Alitretinoin—Flushing—Cisplatin—esophageal cancer	0.000179	0.00153	CcSEcCtD
Alitretinoin—Abdominal distension—Capecitabine—esophageal cancer	0.000178	0.00153	CcSEcCtD
Alitretinoin—Asthma—Capecitabine—esophageal cancer	0.000177	0.00152	CcSEcCtD
Alitretinoin—Dysphagia—Capecitabine—esophageal cancer	0.000177	0.00152	CcSEcCtD
Alitretinoin—Diabetes mellitus—Methotrexate—esophageal cancer	0.000175	0.00151	CcSEcCtD
Alitretinoin—Bronchospasm—Capecitabine—esophageal cancer	0.000174	0.0015	CcSEcCtD
Alitretinoin—Photosensitivity—Methotrexate—esophageal cancer	0.000174	0.00149	CcSEcCtD
Alitretinoin—Sweating increased—Capecitabine—esophageal cancer	0.000173	0.00148	CcSEcCtD
Alitretinoin—Arrhythmia—Cisplatin—esophageal cancer	0.000172	0.00148	CcSEcCtD
Alitretinoin—Alopecia—Cisplatin—esophageal cancer	0.00017	0.00146	CcSEcCtD
Alitretinoin—Abdominal discomfort—Capecitabine—esophageal cancer	0.00017	0.00146	CcSEcCtD
Alitretinoin—Erythema—Cisplatin—esophageal cancer	0.000167	0.00144	CcSEcCtD
Alitretinoin—Malnutrition—Cisplatin—esophageal cancer	0.000167	0.00144	CcSEcCtD
Alitretinoin—Neutropenia—Capecitabine—esophageal cancer	0.000166	0.00142	CcSEcCtD
Alitretinoin—Dysuria—Capecitabine—esophageal cancer	0.000166	0.00142	CcSEcCtD
Alitretinoin—Renal failure acute—Methotrexate—esophageal cancer	0.000165	0.00142	CcSEcCtD
Alitretinoin—Flatulence—Cisplatin—esophageal cancer	0.000165	0.00142	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000165	0.00142	CcSEcCtD
Alitretinoin—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000162	0.00139	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000162	0.00139	CcSEcCtD
Alitretinoin—Weight increased—Capecitabine—esophageal cancer	0.000161	0.00139	CcSEcCtD
Alitretinoin—Visual disturbance—Methotrexate—esophageal cancer	0.000161	0.00138	CcSEcCtD
Alitretinoin—Weight decreased—Capecitabine—esophageal cancer	0.00016	0.00138	CcSEcCtD
Alitretinoin—Pneumonia—Capecitabine—esophageal cancer	0.000159	0.00137	CcSEcCtD
Alitretinoin—Infestation NOS—Capecitabine—esophageal cancer	0.000158	0.00136	CcSEcCtD
Alitretinoin—Infestation—Capecitabine—esophageal cancer	0.000158	0.00136	CcSEcCtD
Alitretinoin—Vision blurred—Cisplatin—esophageal cancer	0.000158	0.00136	CcSEcCtD
Alitretinoin—Depression—Capecitabine—esophageal cancer	0.000158	0.00135	CcSEcCtD
Alitretinoin—Tremor—Cisplatin—esophageal cancer	0.000157	0.00135	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000157	0.00135	CcSEcCtD
Alitretinoin—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000156	0.00134	CcSEcCtD
Alitretinoin—Lethargy—Methotrexate—esophageal cancer	0.000156	0.00134	CcSEcCtD
Alitretinoin—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000156	0.00134	CcSEcCtD
Alitretinoin—Ill-defined disorder—Cisplatin—esophageal cancer	0.000155	0.00134	CcSEcCtD
Alitretinoin—Renal failure—Capecitabine—esophageal cancer	0.000155	0.00133	CcSEcCtD
Alitretinoin—Myocardial infarction—Capecitabine—esophageal cancer	0.000155	0.00133	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000155	0.00133	CcSEcCtD
Alitretinoin—Anaemia—Cisplatin—esophageal cancer	0.000155	0.00133	CcSEcCtD
Alitretinoin—Stomatitis—Capecitabine—esophageal cancer	0.000154	0.00132	CcSEcCtD
Alitretinoin—Conjunctivitis—Capecitabine—esophageal cancer	0.000154	0.00132	CcSEcCtD
Alitretinoin—Urinary tract infection—Capecitabine—esophageal cancer	0.000154	0.00132	CcSEcCtD
Alitretinoin—Osteoarthritis—Methotrexate—esophageal cancer	0.000153	0.00131	CcSEcCtD
Alitretinoin—Malaise—Cisplatin—esophageal cancer	0.000151	0.0013	CcSEcCtD
Alitretinoin—Haematuria—Capecitabine—esophageal cancer	0.000151	0.00129	CcSEcCtD
Alitretinoin—Epistaxis—Capecitabine—esophageal cancer	0.000149	0.00128	CcSEcCtD
Alitretinoin—Agranulocytosis—Capecitabine—esophageal cancer	0.000147	0.00127	CcSEcCtD
Alitretinoin—Irritability—Methotrexate—esophageal cancer	0.000146	0.00125	CcSEcCtD
Alitretinoin—Convulsion—Cisplatin—esophageal cancer	0.000145	0.00125	CcSEcCtD
Alitretinoin—Mood swings—Methotrexate—esophageal cancer	0.000145	0.00124	CcSEcCtD
Alitretinoin—Myalgia—Cisplatin—esophageal cancer	0.000143	0.00123	CcSEcCtD
Alitretinoin—Haemoglobin—Capecitabine—esophageal cancer	0.000143	0.00123	CcSEcCtD
Alitretinoin—Anxiety—Cisplatin—esophageal cancer	0.000142	0.00122	CcSEcCtD
Alitretinoin—Haemorrhage—Capecitabine—esophageal cancer	0.000142	0.00122	CcSEcCtD
Alitretinoin—Hepatitis—Capecitabine—esophageal cancer	0.000142	0.00122	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000142	0.00122	CcSEcCtD
Alitretinoin—Hypoaesthesia—Capecitabine—esophageal cancer	0.000141	0.00121	CcSEcCtD
Alitretinoin—Discomfort—Cisplatin—esophageal cancer	0.000141	0.00121	CcSEcCtD
Alitretinoin—Pharyngitis—Capecitabine—esophageal cancer	0.000141	0.00121	CcSEcCtD
Alitretinoin—Urinary tract disorder—Capecitabine—esophageal cancer	0.00014	0.0012	CcSEcCtD
Alitretinoin—Oedema peripheral—Capecitabine—esophageal cancer	0.00014	0.0012	CcSEcCtD
Alitretinoin—Urethral disorder—Capecitabine—esophageal cancer	0.000139	0.00119	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000137	0.00118	CcSEcCtD
Alitretinoin—Anaphylactic shock—Cisplatin—esophageal cancer	0.000137	0.00117	CcSEcCtD
Alitretinoin—Oedema—Cisplatin—esophageal cancer	0.000137	0.00117	CcSEcCtD
Alitretinoin—Visual impairment—Capecitabine—esophageal cancer	0.000137	0.00117	CcSEcCtD
Alitretinoin—Infection—Cisplatin—esophageal cancer	0.000136	0.00117	CcSEcCtD
Alitretinoin—Erythema multiforme—Capecitabine—esophageal cancer	0.000134	0.00115	CcSEcCtD
Alitretinoin—Nervous system disorder—Cisplatin—esophageal cancer	0.000134	0.00115	CcSEcCtD
Alitretinoin—Thrombocytopenia—Cisplatin—esophageal cancer	0.000134	0.00115	CcSEcCtD
Alitretinoin—ABCB1—lymph node—esophageal cancer	0.000133	0.00391	CbGeAlD
Alitretinoin—Tachycardia—Cisplatin—esophageal cancer	0.000133	0.00115	CcSEcCtD
Alitretinoin—Skin disorder—Cisplatin—esophageal cancer	0.000133	0.00114	CcSEcCtD
Alitretinoin—Eye disorder—Capecitabine—esophageal cancer	0.000133	0.00114	CcSEcCtD
Alitretinoin—Tinnitus—Capecitabine—esophageal cancer	0.000132	0.00114	CcSEcCtD
Alitretinoin—Hyperhidrosis—Cisplatin—esophageal cancer	0.000132	0.00114	CcSEcCtD
Alitretinoin—Asthma—Methotrexate—esophageal cancer	0.000132	0.00113	CcSEcCtD
Alitretinoin—Flushing—Capecitabine—esophageal cancer	0.000132	0.00113	CcSEcCtD
Alitretinoin—Anorexia—Cisplatin—esophageal cancer	0.00013	0.00112	CcSEcCtD
Alitretinoin—Pancreatitis—Methotrexate—esophageal cancer	0.000129	0.00111	CcSEcCtD
Alitretinoin—Angiopathy—Capecitabine—esophageal cancer	0.000129	0.00111	CcSEcCtD
Alitretinoin—Hypotension—Cisplatin—esophageal cancer	0.000128	0.0011	CcSEcCtD
Alitretinoin—Chills—Capecitabine—esophageal cancer	0.000127	0.00109	CcSEcCtD
Alitretinoin—Arrhythmia—Capecitabine—esophageal cancer	0.000127	0.00109	CcSEcCtD
Alitretinoin—Abdominal discomfort—Methotrexate—esophageal cancer	0.000126	0.00109	CcSEcCtD
Alitretinoin—Alopecia—Capecitabine—esophageal cancer	0.000125	0.00108	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000125	0.00107	CcSEcCtD
Alitretinoin—Mental disorder—Capecitabine—esophageal cancer	0.000124	0.00107	CcSEcCtD
Alitretinoin—Erythema—Capecitabine—esophageal cancer	0.000123	0.00106	CcSEcCtD
Alitretinoin—Malnutrition—Capecitabine—esophageal cancer	0.000123	0.00106	CcSEcCtD
Alitretinoin—Dysuria—Methotrexate—esophageal cancer	0.000123	0.00106	CcSEcCtD
Alitretinoin—Neutropenia—Methotrexate—esophageal cancer	0.000123	0.00106	CcSEcCtD
Alitretinoin—Paraesthesia—Cisplatin—esophageal cancer	0.000123	0.00105	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000123	0.00105	CcSEcCtD
Alitretinoin—Dyspnoea—Cisplatin—esophageal cancer	0.000122	0.00105	CcSEcCtD
Alitretinoin—Flatulence—Capecitabine—esophageal cancer	0.000122	0.00105	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00012	0.00103	CcSEcCtD
Alitretinoin—Back pain—Capecitabine—esophageal cancer	0.000119	0.00103	CcSEcCtD
Alitretinoin—Decreased appetite—Cisplatin—esophageal cancer	0.000119	0.00102	CcSEcCtD
Alitretinoin—Pneumonia—Methotrexate—esophageal cancer	0.000118	0.00102	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000118	0.00101	CcSEcCtD
Alitretinoin—Drowsiness—Methotrexate—esophageal cancer	0.000118	0.00101	CcSEcCtD
Alitretinoin—Infestation NOS—Methotrexate—esophageal cancer	0.000118	0.00101	CcSEcCtD
Alitretinoin—Infestation—Methotrexate—esophageal cancer	0.000118	0.00101	CcSEcCtD
Alitretinoin—Depression—Methotrexate—esophageal cancer	0.000117	0.00101	CcSEcCtD
Alitretinoin—Pain—Cisplatin—esophageal cancer	0.000117	0.001	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000117	0.001	CcSEcCtD
Alitretinoin—Vision blurred—Capecitabine—esophageal cancer	0.000116	0.001	CcSEcCtD
Alitretinoin—Tremor—Capecitabine—esophageal cancer	0.000116	0.000994	CcSEcCtD
Alitretinoin—Renal failure—Methotrexate—esophageal cancer	0.000116	0.000994	CcSEcCtD
Alitretinoin—Stomatitis—Methotrexate—esophageal cancer	0.000115	0.000985	CcSEcCtD
Alitretinoin—Ill-defined disorder—Capecitabine—esophageal cancer	0.000115	0.000985	CcSEcCtD
Alitretinoin—Conjunctivitis—Methotrexate—esophageal cancer	0.000114	0.000983	CcSEcCtD
Alitretinoin—Anaemia—Capecitabine—esophageal cancer	0.000114	0.000981	CcSEcCtD
Alitretinoin—Sweating—Methotrexate—esophageal cancer	0.000113	0.000969	CcSEcCtD
Alitretinoin—Feeling abnormal—Cisplatin—esophageal cancer	0.000113	0.000968	CcSEcCtD
Alitretinoin—Haematuria—Methotrexate—esophageal cancer	0.000112	0.000964	CcSEcCtD
Alitretinoin—Malaise—Capecitabine—esophageal cancer	0.000111	0.000957	CcSEcCtD
Alitretinoin—Epistaxis—Methotrexate—esophageal cancer	0.000111	0.000953	CcSEcCtD
Alitretinoin—Syncope—Capecitabine—esophageal cancer	0.000111	0.000952	CcSEcCtD
Alitretinoin—Agranulocytosis—Methotrexate—esophageal cancer	0.00011	0.000943	CcSEcCtD
Alitretinoin—Palpitations—Capecitabine—esophageal cancer	0.000109	0.000938	CcSEcCtD
Alitretinoin—Loss of consciousness—Capecitabine—esophageal cancer	0.000109	0.000933	CcSEcCtD
Alitretinoin—Body temperature increased—Cisplatin—esophageal cancer	0.000108	0.000929	CcSEcCtD
Alitretinoin—Cough—Capecitabine—esophageal cancer	0.000108	0.000926	CcSEcCtD
Alitretinoin—Hypertension—Capecitabine—esophageal cancer	0.000107	0.000916	CcSEcCtD
Alitretinoin—Haemoglobin—Methotrexate—esophageal cancer	0.000106	0.000912	CcSEcCtD
Alitretinoin—Haemorrhage—Methotrexate—esophageal cancer	0.000106	0.000907	CcSEcCtD
Alitretinoin—Hepatitis—Methotrexate—esophageal cancer	0.000106	0.000907	CcSEcCtD
Alitretinoin—Myalgia—Capecitabine—esophageal cancer	0.000105	0.000903	CcSEcCtD
Alitretinoin—Arthralgia—Capecitabine—esophageal cancer	0.000105	0.000903	CcSEcCtD
Alitretinoin—Chest pain—Capecitabine—esophageal cancer	0.000105	0.000903	CcSEcCtD
Alitretinoin—Pharyngitis—Methotrexate—esophageal cancer	0.000105	0.000901	CcSEcCtD
Alitretinoin—Anxiety—Capecitabine—esophageal cancer	0.000105	0.0009	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000104	0.000897	CcSEcCtD
Alitretinoin—Urinary tract disorder—Methotrexate—esophageal cancer	0.000104	0.000896	CcSEcCtD
Alitretinoin—Discomfort—Capecitabine—esophageal cancer	0.000104	0.000893	CcSEcCtD
Alitretinoin—Urethral disorder—Methotrexate—esophageal cancer	0.000103	0.00089	CcSEcCtD
Alitretinoin—Dry mouth—Capecitabine—esophageal cancer	0.000103	0.000884	CcSEcCtD
Alitretinoin—Visual impairment—Methotrexate—esophageal cancer	0.000102	0.000874	CcSEcCtD
Alitretinoin—Confusional state—Capecitabine—esophageal cancer	0.000102	0.000873	CcSEcCtD
Alitretinoin—Oedema—Capecitabine—esophageal cancer	0.000101	0.000866	CcSEcCtD
Alitretinoin—Hypersensitivity—Cisplatin—esophageal cancer	0.000101	0.000866	CcSEcCtD
Alitretinoin—Infection—Capecitabine—esophageal cancer	0.0001	0.00086	CcSEcCtD
Alitretinoin—Erythema multiforme—Methotrexate—esophageal cancer	9.98e-05	0.000858	CcSEcCtD
Alitretinoin—Shock—Capecitabine—esophageal cancer	9.91e-05	0.000852	CcSEcCtD
Alitretinoin—Nervous system disorder—Capecitabine—esophageal cancer	9.88e-05	0.000849	CcSEcCtD
Alitretinoin—Eye disorder—Methotrexate—esophageal cancer	9.87e-05	0.000848	CcSEcCtD
Alitretinoin—Thrombocytopenia—Capecitabine—esophageal cancer	9.87e-05	0.000848	CcSEcCtD
Alitretinoin—Tinnitus—Methotrexate—esophageal cancer	9.84e-05	0.000846	CcSEcCtD
Alitretinoin—Tachycardia—Capecitabine—esophageal cancer	9.83e-05	0.000845	CcSEcCtD
Alitretinoin—Asthenia—Cisplatin—esophageal cancer	9.81e-05	0.000843	CcSEcCtD
Alitretinoin—Skin disorder—Capecitabine—esophageal cancer	9.79e-05	0.000841	CcSEcCtD
Alitretinoin—Hyperhidrosis—Capecitabine—esophageal cancer	9.74e-05	0.000837	CcSEcCtD
Alitretinoin—Anorexia—Capecitabine—esophageal cancer	9.6e-05	0.000826	CcSEcCtD
Alitretinoin—Angiopathy—Methotrexate—esophageal cancer	9.58e-05	0.000823	CcSEcCtD
Alitretinoin—Chills—Methotrexate—esophageal cancer	9.47e-05	0.000814	CcSEcCtD
Alitretinoin—Hypotension—Capecitabine—esophageal cancer	9.42e-05	0.000809	CcSEcCtD
Alitretinoin—Diarrhoea—Cisplatin—esophageal cancer	9.35e-05	0.000804	CcSEcCtD
Alitretinoin—Alopecia—Methotrexate—esophageal cancer	9.33e-05	0.000802	CcSEcCtD
Alitretinoin—Mental disorder—Methotrexate—esophageal cancer	9.25e-05	0.000795	CcSEcCtD
Alitretinoin—Malnutrition—Methotrexate—esophageal cancer	9.19e-05	0.00079	CcSEcCtD
Alitretinoin—Erythema—Methotrexate—esophageal cancer	9.19e-05	0.00079	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	9.18e-05	0.000789	CcSEcCtD
Alitretinoin—Insomnia—Capecitabine—esophageal cancer	9.11e-05	0.000783	CcSEcCtD
Alitretinoin—Paraesthesia—Capecitabine—esophageal cancer	9.05e-05	0.000778	CcSEcCtD
Alitretinoin—Dyspnoea—Capecitabine—esophageal cancer	8.98e-05	0.000772	CcSEcCtD
Alitretinoin—Back pain—Methotrexate—esophageal cancer	8.89e-05	0.000764	CcSEcCtD
Alitretinoin—Dyspepsia—Capecitabine—esophageal cancer	8.87e-05	0.000762	CcSEcCtD
Alitretinoin—Decreased appetite—Capecitabine—esophageal cancer	8.76e-05	0.000753	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Capecitabine—esophageal cancer	8.7e-05	0.000748	CcSEcCtD
Alitretinoin—Vomiting—Cisplatin—esophageal cancer	8.69e-05	0.000747	CcSEcCtD
Alitretinoin—Fatigue—Capecitabine—esophageal cancer	8.69e-05	0.000747	CcSEcCtD
Alitretinoin—Vision blurred—Methotrexate—esophageal cancer	8.66e-05	0.000744	CcSEcCtD
Alitretinoin—Rash—Cisplatin—esophageal cancer	8.62e-05	0.000741	CcSEcCtD
Alitretinoin—Constipation—Capecitabine—esophageal cancer	8.62e-05	0.000741	CcSEcCtD
Alitretinoin—Pain—Capecitabine—esophageal cancer	8.62e-05	0.000741	CcSEcCtD
Alitretinoin—Dermatitis—Cisplatin—esophageal cancer	8.61e-05	0.00074	CcSEcCtD
Alitretinoin—Ill-defined disorder—Methotrexate—esophageal cancer	8.53e-05	0.000733	CcSEcCtD
Alitretinoin—Anaemia—Methotrexate—esophageal cancer	8.49e-05	0.00073	CcSEcCtD
Alitretinoin—Feeling abnormal—Capecitabine—esophageal cancer	8.3e-05	0.000714	CcSEcCtD
Alitretinoin—Malaise—Methotrexate—esophageal cancer	8.29e-05	0.000712	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Capecitabine—esophageal cancer	8.24e-05	0.000708	CcSEcCtD
Alitretinoin—Nausea—Cisplatin—esophageal cancer	8.12e-05	0.000698	CcSEcCtD
Alitretinoin—Cough—Methotrexate—esophageal cancer	8.02e-05	0.000689	CcSEcCtD
Alitretinoin—Urticaria—Capecitabine—esophageal cancer	8e-05	0.000688	CcSEcCtD
Alitretinoin—Abdominal pain—Capecitabine—esophageal cancer	7.97e-05	0.000685	CcSEcCtD
Alitretinoin—Body temperature increased—Capecitabine—esophageal cancer	7.97e-05	0.000685	CcSEcCtD
Alitretinoin—Convulsion—Methotrexate—esophageal cancer	7.96e-05	0.000684	CcSEcCtD
Alitretinoin—Arthralgia—Methotrexate—esophageal cancer	7.82e-05	0.000673	CcSEcCtD
Alitretinoin—Chest pain—Methotrexate—esophageal cancer	7.82e-05	0.000673	CcSEcCtD
Alitretinoin—Myalgia—Methotrexate—esophageal cancer	7.82e-05	0.000673	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	7.77e-05	0.000668	CcSEcCtD
Alitretinoin—Discomfort—Methotrexate—esophageal cancer	7.73e-05	0.000664	CcSEcCtD
Alitretinoin—Confusional state—Methotrexate—esophageal cancer	7.56e-05	0.00065	CcSEcCtD
Alitretinoin—Anaphylactic shock—Methotrexate—esophageal cancer	7.5e-05	0.000645	CcSEcCtD
Alitretinoin—Infection—Methotrexate—esophageal cancer	7.45e-05	0.00064	CcSEcCtD
Alitretinoin—Hypersensitivity—Capecitabine—esophageal cancer	7.42e-05	0.000638	CcSEcCtD
Alitretinoin—Nervous system disorder—Methotrexate—esophageal cancer	7.36e-05	0.000632	CcSEcCtD
Alitretinoin—Thrombocytopenia—Methotrexate—esophageal cancer	7.34e-05	0.000631	CcSEcCtD
Alitretinoin—Skin disorder—Methotrexate—esophageal cancer	7.29e-05	0.000626	CcSEcCtD
Alitretinoin—Hyperhidrosis—Methotrexate—esophageal cancer	7.25e-05	0.000623	CcSEcCtD
Alitretinoin—Asthenia—Capecitabine—esophageal cancer	7.23e-05	0.000621	CcSEcCtD
Alitretinoin—Anorexia—Methotrexate—esophageal cancer	7.15e-05	0.000615	CcSEcCtD
Alitretinoin—Pruritus—Capecitabine—esophageal cancer	7.13e-05	0.000613	CcSEcCtD
Alitretinoin—Hypotension—Methotrexate—esophageal cancer	7.01e-05	0.000602	CcSEcCtD
Alitretinoin—Diarrhoea—Capecitabine—esophageal cancer	6.89e-05	0.000593	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	6.83e-05	0.000587	CcSEcCtD
Alitretinoin—Insomnia—Methotrexate—esophageal cancer	6.78e-05	0.000583	CcSEcCtD
Alitretinoin—Paraesthesia—Methotrexate—esophageal cancer	6.74e-05	0.000579	CcSEcCtD
Alitretinoin—Dyspnoea—Methotrexate—esophageal cancer	6.69e-05	0.000575	CcSEcCtD
Alitretinoin—Somnolence—Methotrexate—esophageal cancer	6.67e-05	0.000573	CcSEcCtD
Alitretinoin—Dizziness—Capecitabine—esophageal cancer	6.66e-05	0.000573	CcSEcCtD
Alitretinoin—Dyspepsia—Methotrexate—esophageal cancer	6.6e-05	0.000568	CcSEcCtD
Alitretinoin—Decreased appetite—Methotrexate—esophageal cancer	6.52e-05	0.00056	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Methotrexate—esophageal cancer	6.48e-05	0.000557	CcSEcCtD
Alitretinoin—Fatigue—Methotrexate—esophageal cancer	6.47e-05	0.000556	CcSEcCtD
Alitretinoin—Pain—Methotrexate—esophageal cancer	6.41e-05	0.000551	CcSEcCtD
Alitretinoin—Vomiting—Capecitabine—esophageal cancer	6.41e-05	0.000551	CcSEcCtD
Alitretinoin—Rash—Capecitabine—esophageal cancer	6.35e-05	0.000546	CcSEcCtD
Alitretinoin—Dermatitis—Capecitabine—esophageal cancer	6.35e-05	0.000546	CcSEcCtD
Alitretinoin—Headache—Capecitabine—esophageal cancer	6.31e-05	0.000543	CcSEcCtD
Alitretinoin—Feeling abnormal—Methotrexate—esophageal cancer	6.18e-05	0.000531	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Methotrexate—esophageal cancer	6.13e-05	0.000527	CcSEcCtD
Alitretinoin—Nausea—Capecitabine—esophageal cancer	5.98e-05	0.000514	CcSEcCtD
Alitretinoin—Urticaria—Methotrexate—esophageal cancer	5.96e-05	0.000512	CcSEcCtD
Alitretinoin—Abdominal pain—Methotrexate—esophageal cancer	5.93e-05	0.00051	CcSEcCtD
Alitretinoin—Body temperature increased—Methotrexate—esophageal cancer	5.93e-05	0.00051	CcSEcCtD
Alitretinoin—Hypersensitivity—Methotrexate—esophageal cancer	5.53e-05	0.000475	CcSEcCtD
Alitretinoin—Asthenia—Methotrexate—esophageal cancer	5.38e-05	0.000463	CcSEcCtD
Alitretinoin—Pruritus—Methotrexate—esophageal cancer	5.31e-05	0.000456	CcSEcCtD
Alitretinoin—Diarrhoea—Methotrexate—esophageal cancer	5.13e-05	0.000441	CcSEcCtD
Alitretinoin—Dizziness—Methotrexate—esophageal cancer	4.96e-05	0.000426	CcSEcCtD
Alitretinoin—Vomiting—Methotrexate—esophageal cancer	4.77e-05	0.00041	CcSEcCtD
Alitretinoin—Rash—Methotrexate—esophageal cancer	4.73e-05	0.000406	CcSEcCtD
Alitretinoin—Dermatitis—Methotrexate—esophageal cancer	4.72e-05	0.000406	CcSEcCtD
Alitretinoin—Headache—Methotrexate—esophageal cancer	4.7e-05	0.000404	CcSEcCtD
Alitretinoin—Nausea—Methotrexate—esophageal cancer	4.46e-05	0.000383	CcSEcCtD
Alitretinoin—RXRB—Generic Transcription Pathway—CREBBP—esophageal cancer	4.45e-05	0.000388	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—NOTCH2—esophageal cancer	4.44e-05	0.000387	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—NOTCH3—esophageal cancer	4.44e-05	0.000387	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.39e-05	0.000382	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.39e-05	0.000382	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	4.37e-05	0.000381	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	4.37e-05	0.000381	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—ABCB1—esophageal cancer	4.29e-05	0.000374	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—ABCB1—esophageal cancer	4.29e-05	0.000374	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—NOTCH3—esophageal cancer	4.26e-05	0.000371	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—NOTCH3—esophageal cancer	4.26e-05	0.000371	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	4.17e-05	0.000363	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—NOTCH2—esophageal cancer	4.13e-05	0.00036	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—NOTCH2—esophageal cancer	4.06e-05	0.000354	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	4.03e-05	0.000351	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—NOTCH2—esophageal cancer	3.98e-05	0.000347	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CA1—esophageal cancer	3.96e-05	0.000345	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—SLC10A2—esophageal cancer	3.96e-05	0.000345	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	3.91e-05	0.000341	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	3.91e-05	0.000341	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	3.88e-05	0.000338	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.82e-05	0.000333	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—NOTCH2—esophageal cancer	3.82e-05	0.000333	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—NOTCH2—esophageal cancer	3.82e-05	0.000333	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	3.81e-05	0.000332	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—CASP8—esophageal cancer	3.8e-05	0.000331	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—SMAD4—esophageal cancer	3.73e-05	0.000325	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	3.69e-05	0.000322	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	3.65e-05	0.000318	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CA2—esophageal cancer	3.62e-05	0.000316	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	3.58e-05	0.000312	CbGpPWpGaD
Alitretinoin—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	3.56e-05	0.000311	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	3.54e-05	0.000309	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—NR1I2—esophageal cancer	3.53e-05	0.000308	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—SMAD4—esophageal cancer	3.47e-05	0.000302	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	3.46e-05	0.000302	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.46e-05	0.000301	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—SMAD4—esophageal cancer	3.41e-05	0.000297	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	3.4e-05	0.000296	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	3.38e-05	0.000295	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—ABL1—esophageal cancer	3.37e-05	0.000294	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PLCE1—esophageal cancer	3.37e-05	0.000294	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ADH7—esophageal cancer	3.37e-05	0.000294	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—SMAD4—esophageal cancer	3.34e-05	0.000291	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.34e-05	0.000291	CbGpPWpGaD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—esophageal cancer	3.33e-05	0.000291	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.33e-05	0.00029	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	3.33e-05	0.00029	CbGpPWpGaD
Alitretinoin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	3.29e-05	0.000287	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—SMAD4—esophageal cancer	3.27e-05	0.000285	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.25e-05	0.000283	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.25e-05	0.000283	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—SMAD4—esophageal cancer	3.21e-05	0.000279	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—SMAD4—esophageal cancer	3.21e-05	0.000279	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.18e-05	0.000277	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	3.18e-05	0.000277	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	3.17e-05	0.000276	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	3.17e-05	0.000276	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—MYC—esophageal cancer	3.07e-05	0.000268	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—HIST1H2BM—esophageal cancer	3.03e-05	0.000264	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	3.01e-05	0.000263	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	2.97e-05	0.000259	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ADH1B—esophageal cancer	2.96e-05	0.000258	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	2.94e-05	0.000256	CbGpPWpGaD
Alitretinoin—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	2.9e-05	0.000253	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.89e-05	0.000252	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	2.88e-05	0.000251	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	2.88e-05	0.000251	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CREBBP—esophageal cancer	2.87e-05	0.00025	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CREBBP—esophageal cancer	2.87e-05	0.00025	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	2.84e-05	0.000247	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—TYMP—esophageal cancer	2.82e-05	0.000246	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—MYC—esophageal cancer	2.81e-05	0.000245	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	2.79e-05	0.000243	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—ABCB1—esophageal cancer	2.77e-05	0.000242	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.77e-05	0.000241	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	2.77e-05	0.000241	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	2.76e-05	0.000241	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	2.76e-05	0.00024	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	2.76e-05	0.00024	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—MYC—esophageal cancer	2.76e-05	0.00024	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—NOTCH1—esophageal cancer	2.75e-05	0.00024	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CYP26A1—esophageal cancer	2.75e-05	0.000239	CbGpPWpGaD
Alitretinoin—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	2.73e-05	0.000238	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.71e-05	0.000236	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	2.7e-05	0.000235	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	2.7e-05	0.000235	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ALOX15—esophageal cancer	2.68e-05	0.000233	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	2.64e-05	0.00023	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—MYC—esophageal cancer	2.64e-05	0.00023	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—MYC—esophageal cancer	2.64e-05	0.00023	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—NOS3—esophageal cancer	2.57e-05	0.000224	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—NOS3—esophageal cancer	2.57e-05	0.000224	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—NOTCH1—esophageal cancer	2.56e-05	0.000223	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—KDR—esophageal cancer	2.56e-05	0.000223	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—TPI1—esophageal cancer	2.55e-05	0.000223	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GSTO1—esophageal cancer	2.55e-05	0.000223	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—NOTCH1—esophageal cancer	2.51e-05	0.000219	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MET—esophageal cancer	2.5e-05	0.000218	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—CREBBP—esophageal cancer	2.49e-05	0.000217	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—NOTCH1—esophageal cancer	2.47e-05	0.000215	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ALDOB—esophageal cancer	2.45e-05	0.000213	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—NOTCH1—esophageal cancer	2.41e-05	0.00021	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—NOTCH1—esophageal cancer	2.36e-05	0.000206	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—NOTCH1—esophageal cancer	2.36e-05	0.000206	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GAPDH—esophageal cancer	2.36e-05	0.000205	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.35e-05	0.000205	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—PSME1—esophageal cancer	2.35e-05	0.000205	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—PSME2—esophageal cancer	2.35e-05	0.000205	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PTGS2—esophageal cancer	2.35e-05	0.000205	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PTGS2—esophageal cancer	2.35e-05	0.000205	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CRABP1—esophageal cancer	2.34e-05	0.000204	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—CREBBP—esophageal cancer	2.32e-05	0.000202	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—CREBBP—esophageal cancer	2.28e-05	0.000199	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.28e-05	0.000198	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—CREBBP—esophageal cancer	2.24e-05	0.000195	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GNG7—esophageal cancer	2.22e-05	0.000194	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—NOTCH3—esophageal cancer	2.22e-05	0.000193	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—CREBBP—esophageal cancer	2.18e-05	0.00019	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—CREBBP—esophageal cancer	2.14e-05	0.000187	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—CREBBP—esophageal cancer	2.14e-05	0.000187	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	2.09e-05	0.000182	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ALDH2—esophageal cancer	2.08e-05	0.000181	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—NOTCH2—esophageal cancer	1.99e-05	0.000173	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GSTT1—esophageal cancer	1.98e-05	0.000173	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CYP2A6—esophageal cancer	1.96e-05	0.000171	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—EP300—esophageal cancer	1.95e-05	0.00017	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—EP300—esophageal cancer	1.95e-05	0.00017	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.95e-05	0.00017	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	1.92e-05	0.000167	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	1.9e-05	0.000165	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	1.87e-05	0.000163	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	1.87e-05	0.000163	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—BLVRB—esophageal cancer	1.86e-05	0.000162	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—SLC52A3—esophageal cancer	1.86e-05	0.000162	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ENO1—esophageal cancer	1.86e-05	0.000162	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PTGS1—esophageal cancer	1.86e-05	0.000162	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.85e-05	0.000162	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PSME1—esophageal cancer	1.83e-05	0.000159	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PSME2—esophageal cancer	1.83e-05	0.000159	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—ERBB2—esophageal cancer	1.83e-05	0.000159	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	1.67e-05	0.000146	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—SMAD4—esophageal cancer	1.67e-05	0.000146	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	1.61e-05	0.00014	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.6e-05	0.000139	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CA1—esophageal cancer	1.58e-05	0.000138	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—SLC10A2—esophageal cancer	1.58e-05	0.000138	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CYP1B1—esophageal cancer	1.58e-05	0.000137	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	1.56e-05	0.000136	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.53e-05	0.000133	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—SLC52A3—esophageal cancer	1.49e-05	0.00013	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—BLVRB—esophageal cancer	1.49e-05	0.00013	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—EP300—esophageal cancer	1.49e-05	0.00013	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CYP19A1—esophageal cancer	1.48e-05	0.000129	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—MYC—esophageal cancer	1.48e-05	0.000129	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CA2—esophageal cancer	1.45e-05	0.000126	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PIK3CA—esophageal cancer	1.45e-05	0.000126	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PIK3CA—esophageal cancer	1.45e-05	0.000126	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.38e-05	0.00012	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—MYC—esophageal cancer	1.38e-05	0.00012	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—HMOX1—esophageal cancer	1.35e-05	0.000118	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—MYC—esophageal cancer	1.35e-05	0.000118	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PLCE1—esophageal cancer	1.35e-05	0.000117	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ADH7—esophageal cancer	1.35e-05	0.000117	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.34e-05	0.000116	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	1.33e-05	0.000116	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.33e-05	0.000116	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—MYC—esophageal cancer	1.33e-05	0.000116	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ABCB1—esophageal cancer	1.3e-05	0.000113	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—MYC—esophageal cancer	1.27e-05	0.000111	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—MYC—esophageal cancer	1.27e-05	0.000111	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.27e-05	0.000111	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—EGFR—esophageal cancer	1.27e-05	0.00011	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CA1—esophageal cancer	1.26e-05	0.00011	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—SLC10A2—esophageal cancer	1.26e-05	0.00011	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—NOTCH1—esophageal cancer	1.23e-05	0.000107	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ADH1B—esophageal cancer	1.18e-05	0.000103	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CA2—esophageal cancer	1.16e-05	0.000101	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.16e-05	0.000101	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.13e-05	9.85e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—TYMP—esophageal cancer	1.13e-05	9.83e-05	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—CREBBP—esophageal cancer	1.12e-05	9.73e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.11e-05	9.65e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.1e-05	9.57e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.08e-05	9.44e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ADH7—esophageal cancer	1.08e-05	9.37e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PLCE1—esophageal cancer	1.08e-05	9.37e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ALOX15—esophageal cancer	1.07e-05	9.32e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.06e-05	9.26e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GSTO1—esophageal cancer	1.02e-05	8.89e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—TPI1—esophageal cancer	1.02e-05	8.89e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.82e-06	8.56e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ALDOB—esophageal cancer	9.79e-06	8.53e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ADH1B—esophageal cancer	9.43e-06	8.22e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GAPDH—esophageal cancer	9.42e-06	8.21e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	9.4e-06	8.19e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CRABP1—esophageal cancer	9.34e-06	8.13e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	9.1e-06	7.93e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—TYMP—esophageal cancer	9.01e-06	7.85e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GNG7—esophageal cancer	8.88e-06	7.74e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP26A1—esophageal cancer	8.76e-06	7.64e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CREBBP—esophageal cancer	8.68e-06	7.57e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ALOX15—esophageal cancer	8.54e-06	7.44e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ALDH2—esophageal cancer	8.32e-06	7.25e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GSTO1—esophageal cancer	8.15e-06	7.1e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—TPI1—esophageal cancer	8.15e-06	7.1e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GSTT1—esophageal cancer	7.91e-06	6.9e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP2A6—esophageal cancer	7.82e-06	6.82e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ALDOB—esophageal cancer	7.81e-06	6.81e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—NOS3—esophageal cancer	7.78e-06	6.78e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GAPDH—esophageal cancer	7.52e-06	6.55e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CRABP1—esophageal cancer	7.45e-06	6.49e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ENO1—esophageal cancer	7.42e-06	6.46e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PTGS1—esophageal cancer	7.42e-06	6.46e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	7.41e-06	6.46e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PSME2—esophageal cancer	7.31e-06	6.37e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PSME1—esophageal cancer	7.31e-06	6.37e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PTGS2—esophageal cancer	7.11e-06	6.2e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GNG7—esophageal cancer	7.09e-06	6.18e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ALDH2—esophageal cancer	6.64e-06	5.79e-05	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—MYC—esophageal cancer	6.63e-06	5.78e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GSTT1—esophageal cancer	6.32e-06	5.51e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP1B1—esophageal cancer	6.31e-06	5.49e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP2A6—esophageal cancer	6.25e-06	5.44e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.22e-06	5.42e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP19A1—esophageal cancer	5.93e-06	5.17e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ENO1—esophageal cancer	5.92e-06	5.16e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PTGS1—esophageal cancer	5.92e-06	5.16e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—EP300—esophageal cancer	5.91e-06	5.15e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PSME1—esophageal cancer	5.83e-06	5.08e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PSME2—esophageal cancer	5.83e-06	5.08e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—HMOX1—esophageal cancer	5.41e-06	4.71e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.09e-06	4.44e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP1B1—esophageal cancer	5.03e-06	4.39e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP19A1—esophageal cancer	4.73e-06	4.12e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PIK3CA—esophageal cancer	4.38e-06	3.81e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—HMOX1—esophageal cancer	4.32e-06	3.76e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.24e-06	3.69e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ABCB1—esophageal cancer	4.15e-06	3.61e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CREBBP—esophageal cancer	3.47e-06	3.02e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.13e-06	2.73e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—NOS3—esophageal cancer	3.11e-06	2.71e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PTGS2—esophageal cancer	2.84e-06	2.48e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CREBBP—esophageal cancer	2.77e-06	2.41e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NOS3—esophageal cancer	2.48e-06	2.16e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—EP300—esophageal cancer	2.36e-06	2.06e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.27e-06	1.98e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—EP300—esophageal cancer	1.89e-06	1.64e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.75e-06	1.52e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.4e-06	1.22e-05	CbGpPWpGaD
